FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes

<b>Background:</b> It has been demonstrated that the concept of infinite absorption time, associated with the absorption rate constant, which drives a drug's gastrointestinal absorption rate, is not physiologically sound. The recent analysis of oral drug absorption data based on the...

Full description

Saved in:
Bibliographic Details
Main Authors: Elias Toulitsis (Author), Athanasios A. Tsekouras (Author), Panos Macheras (Author)
Format: Book
Published: MDPI AG, 2024-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8476a484ae2b41da9a837cdcbbb54c5d
042 |a dc 
100 1 0 |a Elias Toulitsis  |e author 
700 1 0 |a Athanasios A. Tsekouras  |e author 
700 1 0 |a Panos Macheras  |e author 
245 0 0 |a FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes 
260 |b MDPI AG,   |c 2024-11-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics16111435 
500 |a 1999-4923 
520 |a <b>Background:</b> It has been demonstrated that the concept of infinite absorption time, associated with the absorption rate constant, which drives a drug's gastrointestinal absorption rate, is not physiologically sound. The recent analysis of oral drug absorption data based on the finite absorption time (F.A.T.) concept and the relevant physiologically based finite-time pharmacokinetic (PBFTPK) models developed provided a better physiologically sound description of oral drug absorption. <b>Methods:</b> In this study, we re-analyzed, using PBFTPK models, seven data sets of ketoprofen, amplodipine, theophylline (three formulations), and two formulations (reference, test) from a levonorgestrel bioequivalence study. Equations for one-compartment-model drugs, for the estimation of fraction of dose absorbed or the bioavailable fraction exclusively from oral data, were developed. <b>Results:</b> In all cases, meaningful estimates for (i) the number of absorption stages, namely, one for ketoprofen and the levonorgestrel formulations, two for amlodipine, the immediate-release theophylline formulation, and the extended-release Theotrim formulation, and three for the extended-release Theodur formulation, (ii) the duration of each absorption stage and the corresponding drug input rate, and (iii) the total duration of drug absorption, which ranged from 0.75 h (ketoprofen) to 11.6 h for Theodur were derived. Estimates for the bioavailable fraction of ketoprofen and two theophylline formulations exhibiting one-compartment-model kinetics were derived. <b>Conclusions:</b> This study provides insights into the detailed characteristics of oral drug absorption. The use of PBFTPK models in drug absorption analysis can be leveraged as a computational framework to discontinue the perpetuation of the mathematical fallacy of classical pharmacokinetic analysis based on the absorption rate constant as well as in the physiologically based pharmacokinetic (PBPK) studies and pharmacometrics. The present study is an additional piece of evidence for the scientific and regulatory changes required to be implemented by the regulatory agencies in the not-too-distant future. 
546 |a EN 
690 |a finite absorption time 
690 |a oral administration 
690 |a fraction absorbed 
690 |a bioavailability 
690 |a levonorgestrel 
690 |a amlodipine 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 16, Iss 11, p 1435 (2024) 
787 0 |n https://www.mdpi.com/1999-4923/16/11/1435 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/8476a484ae2b41da9a837cdcbbb54c5d  |z Connect to this object online.